HHS Colony Stimulating Factor 2013-2018

The HHS Colony Stimulating Factor 2013-2018 Master Indefinite Delivery/Indefinite Quantity (IDIQ) contract is a specialized medical countermeasure procurement vehicle focused on acquiring colony stimulating factors (G-CSF or GM-CSF) to mitigate neutropenia arising from potential exposure to ionizing radiation. The contract, awarded by the Department of Health and Human Services (HHS) Office of the Assistant Secretary for Preparedness and Response (ASPR), enables the strategic acquisition of critical medical treatments designed to address neutrophil degradation in potential radiation exposure scenarios. This vehicle supports HHS's national medical emergency preparedness strategy by maintaining a forward-deployable supply of specific medical interventions.

The contract has primarily awarded task orders to two prime contractors: Amgen USA Inc. and Partner Therapeutics, Inc., with contract values ranging from approximately $13.9 million to $154.4 million. The most recent task orders have ultimate completion dates through March 2024, indicating a consistent multi-year strategy for medical countermeasure procurement. Each task order is structured as a firm fixed-price delivery order with no specific set-aside designations, reflecting a competitive, open procurement approach. Contractors are predominantly located in California (Amgen in Thousand Oaks) and Massachusetts (Partner Therapeutics in Lexington), suggesting a concentration of specialized pharmaceutical capabilities in these regions. The task orders consistently focus on the acquisition of colony stimulating factors for neutropenia mitigation, highlighting a precise and targeted medical intervention strategy.